Answers are grounded in this paper and cite their sources.
Synthesis of novel ligands improves dopamine D4 receptor engagement, suggesting therapeutic potential for schizophrenia.
The dopamine D4 receptor is highly expressed in prefrontal cortex, hippocampus, amygdala, hypothalamus and is hypothesized to relate with the pathophysiology and pharmacotherapy of schizophrenia while its level in brain regions is much lower. To date, no specific ligand is available for the study of D4 receptor in vivo. In this study, we report the synthesis and in vitro receptor binding assay of three benzopyrano[3,4-c]pyridin-5-ones as potential dopamine D4 receptor ligands. These new compounds have higher affinity and selectivity toward dopamine D4 receptor and their K i values for D4 receptor are in the nanomolar (nM) range.
No takes yet. Share an insight, caveat, or question.
Li et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: